35 results about "Thrombolytic drug" patented technology

The application discloses a four-stage paddle thrombus-removing micro robot, a preparation method and a magnetic field driving thrombus-removing micro robot system, relates to the technical field of micro robots, and comprises a conical drill bit, a main straight rod and a four-stage paddle group, wherein the conical drill bit is made of a biodegradable material; the bottom of the conical drill bit is connected with the main straight rod; the main straight rod is internally provided with a thrombolytic drug; the four-stage paddle group is arranged on the outer circumferential surface of the main straight rod in an axial direction; the paddle group comprises three paddle blades which are centrally symmetrical to the axis of the main straight rod; the paddle blades in the adjacent two-stage paddle groups are arranged in a staggered manner; the paddle blades are of a round head structure; the thickness of the paddle blades gradually increases from outside to inside; and the surface of the micro robot is coated with a magnetic film and is subjected to directional magnetization treatment. The application can obtain strong movement ability and stable movement state under the accurate control of a movement system, realizes intravascular drilling and crushing of a thrombus, and can biodegrade and release the thrombolytic drug after surgery, so as to solve the problem of downstream vascular embolism after drilling.

The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.

The invention discloses a cerebral apoplexy thrombolysis patient evaluation method, device and equipment and a storage medium, and the evaluation method comprises the steps: obtaining patient information, obtaining the weight data of a patient from a record database, reading the type of a drug, obtaining a dose coefficient and a conversion factor from a drug database, dose data of the thrombolytic drug is calculated through a first formula and is sent to the display module to be displayed, rapid conversion of the administration dose is achieved, calculation errors of the thrombolytic drug dose are avoided, then blood pressure data, heart rate data and blood oxygen saturation data of a patient are obtained in real time, and the accuracy of thrombolytic drug dose calculation is improved. And judging whether the vital signs are correspondingly located in the first range, the second range and the third range or not, and if not, sending out an alarm signal, so as to accurately judge the vital sign data of the thrombolysis patient, timely discover abnormity and send out an early warning.

This invention provides a thrombolytic catheter system for cerebral venous sinus, relating to the field of medical device technology. It includes a microcatheter and a blocking guidewire. The microcatheter has a drug injection structure and side holes. The side holes have several through-holes distributed circumferentially and axially. The blocking guidewire includes a guidewire body and a blocking portion connected to the guidewire body. By using the microcatheter and blocking guidewire, during use, the blocking guidewire is inserted into the microcatheter, and the blocking portion at the end of the guidewire seals the end of the catheter. Thus, during thrombolytic drug injection, the drug only flows out from the through-holes of the catheter. Multiple through-holes are provided circumferentially and axially. This closed design, where thrombolytic drug flows only from the side holes, increases the contact area between the thrombolytic drug and the thrombus, thereby increasing the probability of vascular patency and reducing catheterization time. This solves problems related to the difficulty of removing cerebral venous sinus thrombi, venous reflux during catheter-based thrombolysis, and intracranial infection.

The invention discloses plasmin based on hermetia illucens and application thereof, and belongs to the technical field of biology. The plasmin based on the hermetia illucens is obtained by grinding and centrifuging larvae of the hermetia illucens in a PBS (Phosphate Buffer Solution) and extracting supernate. The invention further provides application of the plasmin based on the hermetia illucens in preparation of thrombolytic drugs. The plasmin is extracted from the hermetia illucens, and the hermetia illucens is short in breeding cycle, high in reproductive capacity, capable of being massively extracted in a short time and low in cost; the extracted plasmin has a remarkable thrombolysis effect and has a very good utilization value; the plasmin can be used for directly dissolving thrombus and degrading fibrinogen.

The invention discloses a medicine injection device capable of realizing automatic thrombolysis administration, which comprises a driving device, a mounting control valve, a thrombolysis medicine bag, a thrombolysis catheter and an injector, the driving device is provided with the mounting control valve, the mounting control valve is connected with the thrombolysis medicine bag, the mounting control valve is connected with the thrombolysis catheter, the mounting control valve is connected with the injector, and the injector is connected with the thrombolysis medicine bag. The driving device comprises a motor and a sensor, the motor is connected with the installation control valve, the sensor is connected with the injector, and the sensor is connected with the motor. By the adoption of the technical scheme, the medicine injection device which is convenient and rapid and capable of achieving automatic thrombolysis medicine administration is manufactured, automatic medicine taking or medicine injection can be achieved by automatically controlling steering of the installation control valve installed on the driving device, and meanwhile an interval medicine administration mode is designed according to the characteristics of thrombolysis medicine administration. And the interval administration time, the pulse amount and the pulse administration rate can be conveniently set clinically, so that personalized thrombolysis administration is realized, and more effective thrombolysis treatment is realized.

The invention relates to the technical field of medical apparatuses and instruments, and provides an ultrasonic thrombolysis guide wire and a treatment system.The ultrasonic thrombolysis guide wire comprises a guide wire body; an ultrasonic transmitting terminal; and the piezoelectric vibration mode transducer is arranged on the ultrasonic transmitting end. According to the ultrasonic thrombolysis guide wire provided by the invention, multidirectional emission of ultrasound can be realized, the coverage range of a sound field on thrombus is widened, and the thrombus can be effectively treated in cooperation with an ultrasonic contrast agent and thrombolysis drugs. The multi-directional ultrasonic emission can be realized by the single transducer, the use of the transducer is reduced, the overall size of the guide wire is smaller, and the requirement of intravascular thrombolysis miniaturization is more easily met. In addition, based on the advantages of the piezoelectric vibration type transducer, the piezoelectric vibration type transducer can emit low-frequency ultrasound under the condition that the small size is maintained, and the applicability is higher.

The invention discloses a fermented soybean fermentation process for high-yield plasmin and thrombolysis application thereof. According to the method, black beans are used as raw materials, water is added for soaking and sterilization, bacillus subtilis is added, the mixture is put into a constant-temperature and constant-humidity incubator for fermentation, according to plasmin activity, the fermentation temperature, humidity, time, inoculation amount, loading capacity and solid-liquid ratio are subjected to a single-factor test, the solid-state fermentation conditions are optimized, and the plasmin solid-state fermentation effect is improved. An optimal solid-state fermentation process is determined by combining an orthogonal test, high-plasmin-yield fermented soybean is obtained through an ultralow-temperature freeze-drying technology, and finally, the safety and thrombolysis effect of the plasmin of the fermented soybean are verified through in-vivo and in-vitro thrombolysis experiments. Compared with the traditional processing process, the fermented soybean processed by the method disclosed by the invention has the advantages that the influence of seasonal and environmental conditions is reduced by utilizing the principle of pure fermentation, the quality stability of the fermented soybean is improved, and meanwhile, the production of the fermented soybean with high plasmin yield lays a foundation for the development of thrombolytic drugs.

The invention discloses a thrombus extraction stent system and a preparation method and application thereof, and belongs to the technical field of medical instruments.The thrombus extraction stent system comprises an expansion stent, a micro catheter and a thrombolysis medicine, and the method comprises the steps that the target dosage of the thrombolysis medicine is determined according to angiography data of target thrombus; determining a first target printing parameter of the thrombolytic drug according to the target dose of the thrombolytic drug; according to the first target printing parameters, a medicine layer containing thrombolytic medicine is formed on the expansion stent through 3D printing, the expansion stent is placed in the micro-catheter, and the thrombectomy stent system is prepared. The technical problem that the thrombolysis medicine cannot be accurately released according to the actual condition of thrombus in the conventional thrombus extraction process is solved.

The embodiment of the invention relates to the technical field of instruments for removing obstruction in blood vessels, in particular to a coronary thrombolysis catheter and a coronary thrombolysis assembly suitable for an ultrasonic guided intervention technology. The catheter includes a catheter assembly disposed to enter the aorta and extend into the left ventricle. The medicine conveying pipe is arranged in the catheter assembly and is arranged to be capable of conveying thrombolytic medicine into the thrombus of the coronary artery through the catheter assembly. The balloon is arranged outside the catheter assembly and can expand after being filled with water, so that the space between the catheter assembly and the aorta is sealed, the thrombolytic medicine cannot flow out of the coronary artery, and thrombus is dissolved. The catheter assembly is configured to allow blood within the left ventricle to flow out through the catheter assembly. According to the catheter, the thrombolytic drug can stay in the coronary artery for a long time, so that the thrombolytic effect and targeting performance are improved, the thrombolytic drug conveyed to the coronary artery is prevented from leaking to the whole body through the aorta, the influence of the thrombolytic drug on the whole body blood coagulation mechanism is reduced, the risk of cerebral hemorrhage and bleeding of other visceral organs is reduced, and the safety of thrombolytic treatment is improved.

An ultrasound catheter with a lumen for fluid delivery and fluid evacuation, and an ultrasound source is used for the treatment of intracerebral or intraventricular hemorrhages. After the catheter is inserted into a blood clot, a lytic drug can be delivered to the blood clot via the lumen while applying ultrasonic energy to the treatment site. As the blood clot is dissolved, the liquefied blood clot can be removed by evacuation through the lumen.

The invention discloses a multistage drug-loaded nano motor and a preparation method and application thereof, the nano motor is based on a magnetic nanoparticle core (Fe3O4), the surface of the nano motor is modified with a mesoporous silica layer of a sandwich structure to load thrombolytic drugs, and the outermost layer is wrapped with polydopamine. The Fe3O4 core enables the nano-particle to target a lesion area through physical adsorption, the sandwich structure further improves the dispersibility and uniformity of the nano-particle, and the polydopamine shell can play photo-thermal thrombolysis, anti-inflammatory and anti-oxidation roles under 808nm laser irradiation, so that systematic treatment for diseases is realized. The preparation method provided by the invention has the advantages of simplicity in operation, high universality, convenience in large-scale production and the like, and the prepared nanoparticles can overcome blood flow resistance, target a focus area and play a comprehensive treatment function, and have potential application prospects and practical significance in the biomedical fields of tissue repair, focus ablation and the like.

The invention discloses an intravascular thrombus treatment method based on a nano-robot cluster, and relates to the field of micro-nano robots, and the method comprises the following steps: S1, transporting a magnetic nano-robot cluster to a target thrombus part through intravenous injection; s2, guiding the nano-robot cluster to gather to the thrombus surface in a targeted manner based on an external gradient magnetic field, and propelling along the blood vessel wall in combination with a shield tunneling machine propelling principle; s3, driving the nano-robot cluster to self-assemble based on an alternating magnetic field to form a micron-sized vortex structure, and destroying a fibrous protein laminar flow barrier on the surface of the thrombus; s4, the nanorobot cluster synchronously releases the thrombolytic drug; s5, after thrombus is removed, the nano-robot cluster is dissociated into single-particle nano-robots, the single-particle nano-robots are discharged out of the body through human metabolism, fluid mechanics optimization and the shield tunneling machine principle are combined, a rotary shear flow field generated by the nano-robot cluster and a drug release system act synergistically, mechanical crushing and chemical thrombolysis are synchronously achieved, and the thrombus removing effect is achieved. And the clearing efficiency is obviously improved.

The invention provides a temperature-controlled thrombolysis device for minimally invasive puncture drainage of acute cholecystitis, and relates to the technical field of medical equipment.The temperature-controlled thrombolysis device comprises an infusion pump and an infusion pipeline leading-out connector, a push plate is pushed to drive two sets of rubber arc-shaped plates to get close to each other until the two sets of rubber arc-shaped plates are completely attached, an infusion tube is wrapped, then a locking screw is rotated, and the infusion tube is wound. The ends of the first heat-preservation arc-shaped strip and the second heat-preservation arc-shaped strip extend into the inner side of the fixing frame and are tightly attached to the outer surface of the push plate, the positions of the push plate and the rubber arc-shaped plate are locked through the jacking force of the locking screw, in the process, the first heat-preservation arc-shaped strip and the second heat-preservation arc-shaped strip are in synchronous butt joint, then the sealing wrapping belt surrounds the butt joint position in the circumferential direction to cover a connector gap, and fixing is completed by pressing the first hook-and-loop fastener and the second hook-and-loop fastener. Finally, the infusion tube is sealed in a space formed by the rubber arc-shaped plate and the heat preservation arc-shaped strip, by means of the low heat conduction characteristic of the heat preservation arc-shaped strip, the preset temperature of thrombolysis medicine in the tube can be stably maintained, interference of temperature fluctuation on the thrombolysis effect is effectively avoided, and the stability and effectiveness of the medicine effect in the treatment process are guaranteed.

The application relates to the field of biological medicine, and particularly discloses a fusion protein and application thereof. The fusion protein is composed of a polypeptide and six histidines, the polypeptide has sequence consistency of at least 9 / 10, 14 / 15 or 29 / 30 with the amino acid sequence shown in SEQ ID NO:1, and the six histidines are located at the C-terminal of the polypeptide. The fusion protein designed in the application is derived from a human body protein, the metabolic product is an amino acid, and therefore the safety is better than that of other therapeutic drugs. Moreover, the fusion protein can significantly reduce the infarction volume of the brain of a tMCAO model mouse, has a significant treatment on ischemic stroke, and has a longer treatment time window than that of an existing thrombolytic drug. Compared with the existing ischemic stroke treatment drug, the human sTREM2-6His fusion protein has a brand-new treatment mechanism and target.

The invention discloses composite lipid nanoparticles as well as a preparation method and application thereof. The composite lipid nanoparticle comprises a lipid outer layer and an internal drug loading core, the lipid outer layer comprises lecithin, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-CREKA, and the internal drug loading core comprises fatty acid and a protein thrombolytic drug. The preparation method comprises the following steps: forming a lipid membrane, preparing a water-phase solution, hydrating the lipid membrane, extruding, filtering and the like. Thrombus targeting is achieved through a CREKA peptide mediated protein crown formation mechanism, the drug encapsulation efficiency is improved to 26.55% through fatty acid, and drug leakage is reduced. The composite lipid nanoparticles provided by the invention have good biocompatibility, can effectively dissolve thrombus and remarkably reduce the bleeding risk, and can be used for preparing medicines for treating thrombus obstructive diseases.

A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a thrombolytic drug and the matrix component includes a hyaluronan or derivative thereof, the matrix component having a viscosity greater than 10 mPa·s.

The invention provides urokinase-loaded exosome-like nano-vesicles as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the urokinase-loaded exosome-like nano-vesicle disclosed by the invention, a thrombolytic drug and inherent active ingredients of radix puerariae are packed in one vesicle, so that the urokinase-loaded exosome-like nano-vesicle is obtained; in the urokinase-loaded exosome-like nano-vesicle, active ingredients of radix puerariae and urokinase can generate a synergistic effect, so that deep vein thrombosis is effectively dissolved, meanwhile, the bleeding risk is reduced, the half-life period of urokinase is prolonged, damaged vascular endothelium is repaired in time, the recurrence rate of thrombosis is reduced, and the urokinase-loaded exosome-like nano-vesicle can be used for treating deep vein thrombosis. The invention provides a new direction and strategy for the development of safe deep vein thrombosis treatment drugs, and has good practicability.

The invention relates to the technical field of medical instruments, in particular to a thrombectomy device which comprises a far-end assembly and a far-end assembly, the far-end assembly comprises a first outer tube and a first inner tube, a first balloon is arranged at the far end of the first inner tube, the first inner tube penetrates through the first outer tube, and a variable-diameter support is connected between the far end of the first outer tube and the first inner tube; the near-end assembly comprises a second outer tube, a second balloon is arranged at the far end of the second outer tube, and the first outer tube can penetrate through the second outer tube, so that the first balloon and the variable-diameter stent extend out of an opening in the far end of the second outer tube, and the variable-diameter stent is located between the first balloon and the second balloon; in the use process, the front side and the rear side of a thrombus are filled with the first balloon and the second balloon respectively so that blood around the thrombus can be blocked from flowing, the thrombus can be cut or captured by adjusting the diameter of the variable-diameter support, thrombolysis medicine is injected to dissolve or soften the thrombus, and the thrombus is drawn back through the second outer tube. And the first balloon is pulled back to recover the stent with the thrombus tissue into the second outer tube.

The invention belongs to the technical field of biological medicine, and particularly relates to a bionic magnetic targeting thrombolysis composite medicine preparation and a preparation method thereof.The bionic magnetic targeting thrombolysis composite medicine preparation is of a multi-layer core-shell structure and comprises a magnetic layer, a mesoporous silica layer, an electropositive polymer protective film layer and a bionic biological film layer which are sequentially distributed from inside to outside; wherein the mesoporous silicon dioxide layer and the interior of the mesoporous silicon dioxide layer are loaded with thrombolytic drugs. On the basis of a targeted thrombus treatment technology of magnetic particles, a thrombolysis drug is carried by the magnetic responsive nano-carrier, accurate navigation to a thrombus lesion area can be realized under the guidance of an external magnetic field, and the drug is quickly released under the irradiation of near-infrared light, so that local efficient thrombolysis is realized.

The application discloses a thrombus removing catheter and belongs to the technical field of cardiovascular treatment instruments. The catheter is internally provided with a hollow catheter, one end of the catheter is internally provided with a blocking plug, the outer wall of the blocking plug is fixed to the inner wall of the catheter, the inside of the catheter is provided with a core tube, the outer surface of the core tube is slidably connected to the middle part of the blocking plug, and the flow gap is arranged between the outer surface of the core tube and the inner wall of the catheter, both ends of the core tube are arranged outside the two end parts of the catheter, the surface of the blocking plug close to the outside is provided with a hollow guide column, the inner surface of the guide column is fixed to the outer surface of the core tube, the guide column comprises a spliced cylindrical end and a tapered end, a plurality of circumferentially distributed guide sliding grooves are arranged on the outer surface of the guide column, and the guide sliding grooves are distributed on the cylindrical end and the tapered end. The technical scheme is used to improve the injection effect of thrombolytic liquid, reduce the thrombolysis time length and improve the thrombolysis efficiency.

The application relates to a pH-sensitive phospholipid-modified nattokinase magnetic-targeting nano-drug liposome and a preparation method thereof. In the application, egg yolk lecithin is selected as basic material of a phospholipid bilayer, DSPE-PEOz2000 is selected as a pH-sensitive material, and magnetic ferroferric oxide nanoparticles are selected as magnetic material. The system is based on pH-sensitive liposomes, and the water phase is loaded with thrombolytic drugs nattokinase and citric acid-modified ferroferric oxide nanoparticles. Compared with traditional drugs, the drug-loaded system can release the drugs at a specific site, maintain the enzyme activity of nattokinase, realize the targeted delivery of thrombolytic drugs, and achieve better thrombolytic effect.

The invention discloses an ischemic cerebrovascular disease traditional Chinese medicine targeted thrombolysis drug delivery device, and belongs to the field of medical instruments, the drug delivery device comprises a catheter body, an inner tube, a drug delivery spray hole, a drug circulation channel, and a displacement mechanism located at the far end of the catheter body, and the inner wall of the inner tube is provided with a passing channel for a guide wire to pass through; the shifting mechanism comprises two balloon sets distributed at the two ends of the dosing spray hole respectively, each balloon set at least comprises four anchoring balloons distributed along the outer wall of the catheter body in an annular array mode, and the four anchoring balloons in each balloon set are independently distributed. The four anchoring balloons in the two balloon groups are arranged in a manner that every two anchoring balloons form one group and are communicated with each other through the independent balloon filling channels. According to the drug delivery device, through active control, it is ensured that the drug delivery spray hole always faces the most concentrated thrombus area, drug waste and meaningless flushing of the blood vessel wall are avoided, and the utilization efficiency and the thrombolysis speed of traditional Chinese medicine thrombolysis drugs are greatly improved.

The utility model provides a double-cavity perfusion thrombolysis microcatheter for uniform administration, and relates to the technical field of double-cavity perfusion thrombolysis microcatheters.The double-cavity perfusion thrombolysis microcatheter comprises a main body mechanism, the main body mechanism comprises an outer tube, a medicine conveying cavity is formed in the outer tube, medicine release holes are formed in the outer surface of the outer tube, an inner tube is connected into the outer tube in a sleeved mode, and the inner tube is provided with a medicine delivery cavity; the inner tube is fixedly connected with the outer tube, a guide wire cavity is formed in the inner tube, a connecting tube is arranged at one end of the outer tube, and the connecting tube is fixedly connected with the outer tube. According to the double-cavity perfusion thrombolysis microcatheter for the interventional operation, the main body mechanism is arranged, so that a guide wire can penetrate through the double-cavity perfusion thrombolysis microcatheter for the interventional operation and medicine can be injected into the double-cavity perfusion thrombolysis microcatheter at the same time when the double-cavity perfusion thrombolysis microcatheter for the interventional operation is used, and when the guide wire enters a blood vessel of a patient, thrombolysis medicine can be released in time, and the purpose of thrombolysis is achieved; and therefore, the life safety of the patient cannot be influenced by drawing the guide wire.

The invention relates to a composite thrombolysis device for intracranial veins and an operation method thereof, and relates to the technical field of medical instruments.The device comprises a thrombolysis catheter assembly which comprises a micro catheter and a blood vessel wall supporting assembly; the blood vessel wall supporting assembly comprises a cylindrical elastic support net arranged at the far end of the micro catheter in a sleeving mode, and the side, close to the near end of the micro catheter, of the cylindrical elastic support net is connected with the outer wall of the micro catheter through an elastic guiding part. The conveying catheter is arranged on the outer wall of the micro catheter in a sliding and sleeving mode so that the blood vessel wall supporting assembly can retract to or be disengaged from the conveying catheter. According to the application, blood vessels can be successfully supported, local blood flow smoothness is recovered, a stable and wide administration environment is provided for subsequent administration of thrombolytic drugs, permanent foreign body implantation to blood vessel walls can be avoided, and the risk of long-term complications is reduced.

The application provides a directional thrombolytic pro-endothelialization composite small-caliber artificial blood vessel and a preparation method thereof. The method activates and chemically modifies the surface of an expanded polytetrafluoroethylene (ePTFE) artificial blood vessel through plasma treatment, introduces active carboxyl groups and covalently grafts a pro-endothelial adhesion polypeptide REDV; then, by using the strong adhesion of a polydopamine (PDA) coating, nano-hydrogel particles loaded with thrombolytic drugs t-PANPs are fixed on the inner surface of the blood vessel. The application actively recruits endothelial cells by the bottom layer of the REDV polypeptide, and at the same time, realizes on-demand and controlled release of t-PA for thrombolysis by the upper layer of the nano-hydrogel, thereby solving the problems of easy thrombosis and intimal hyperplasia of the small-caliber artificial blood vessel. The preparation process condition is mild, the performance is stable, the synergistic effect of antithrombosis and pro-endothelialization is realized, and the application has a good clinical application prospect.

The utility model relates to medical instrument technical field provides a kind of thrombolytic catheter set, comprising: thrombolytic catheter, the thrombolytic catheter includes catheter main body, the distal end of the catheter main body is the curved section of pigtail type, the curved section is made of flexible hose, and a plurality of liquid outlet holes are arranged on the pipe wall of the curved section.The utility model provides a kind of thrombolytic catheter set, including thrombolytic catheter, thrombolytic catheter includes catheter main body, the distal end of the catheter main body is the curved section of pigtail type, the curved section is made of flexible hose, and a plurality of liquid outlet holes are arranged on the pipe wall of the curved section;Such setting can increase the accessible range of thrombolytic drug, so that thrombolytic drug acting area and intensity are enhanced, and the drug ejected has certain cutting effect on thrombus, further increases the drug acting area, is favorable to improve thrombolysis efficiency and effect.

This invention provides a thrombolysis catheter structure and an interventional device for thrombosis treatment, relating to thrombosis treatment medical devices. The device includes a thrombolysis catheter and a thrombolysis head. The proximal end of the thrombolysis catheter is connected to an ultrasonic transducer to receive vibrational energy. The thrombolysis catheter also has a first inlet for introducing thrombolytic agents. The thrombolysis head is fixedly connected to the distal end of the thrombolysis catheter, and the diameter of the thrombolysis head is larger than the diameter of the thrombolysis catheter. The thrombolysis head has a drug chamber that communicates with the distal end of the thrombolysis catheter. The thrombolysis head also has a spray hole communicating with the drug chamber, facing distally. This invention enables simultaneous ultrasonic thrombolysis and drug thrombolysis, allowing mechanical thrombolysis and drug thrombolysis to act simultaneously on the same area of ​​the thrombus, significantly improving thrombosis treatment efficiency. Furthermore, since thrombolysis and thrombolysis are performed concurrently, there is no need to change surgical instruments multiple times to perform the thrombolysis and thrombolysis processes separately, which helps to shorten the operation time.

Provided is a thrombolytic agent for ‘intravascular thrombus’, and more particularly, to a thrombolytic agent having a thrombo-recognition domain and a thrombolytic domain. It also relates to a polypeptide for thrombolysis of an intravascular thrombus, a gene for that polypeptide, and a pharmaceutical composition containing the same. The polypeptide that recognizes ‘intravascular thrombus’ and dissolves thrombus of the present invention is characterized in that it consists of a thrombolytic domain comprising the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 and a thrombo-recognition domain comprising the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4. According to the present invention, the polypeptide for dissolving thrombus by recognizing ‘intravascular thrombus’ dissolves thrombus in the blood of a mammal without serious bleeding side effects has a preventive and therapeutic effect on thrombosis, thus preventing thrombosis and related diseases.